Han KA, et al. - Researchers conducted this double-blind, placebo-controlled, multi-center, phase 3 study in Korea from 2015 to 2017 to assess the effectiveness and safety of ipragliflozin vs placebo as add-on therapy to metformin and sitagliptin in Korean patients with type 2 diabetes mellitus (T2DM). Participants in the study were randomized to receive either ipragliflozin 50 mg/day or placebo once daily for 24 weeks, in addition to metformin and sitagliptin. In Korean patients with inadequately controlled T2DM, ipragliflozin added-on to metformin and sitagliptin significantly improved glycemic measures and showed a good safety profile.